https://www.prnewswire.co.uk/news-releases/first-patient-dosed-in-phase-ii-starburst-study-of-tlx250-cdx-exploring-indication-expansion-301853801.html
First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the...